[1] STOPPA A, ANMELLA G, DELGADO L, et al.A manic episode with psychotic features associated with levetiracetam: a case report, a proposal of prodromal and discriminative symptoms and a possible pathophysiological mechanism[J]. J Clin Psychopharmacol, 2022, 42(3): 316-317. [2] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245. [3] Chinese Journal of Pharmacovigilance. System-organ code search involved in the WHO adverse drug reaction terminology set[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2008, 5(4): 255-256. [4] Ministry of Health of the People's Republic of China. Administrative Measures on Reporting and Monitoring of adverse drug reaction (药品不良反应报告和监测管理办法)[EB/OL]. (2011-05-04) [2011-05-24]. https://www.gov.cn/zhengce/2011-05/24/content_2603398.htm. [5] ZOU X, HONG Z, ZHOU D.Hair loss with levetiracetam in five patients with epilepsy[J]. Seizure, 2014, 23(2): 158-160. [6] SELVARAJ V, MADABUSHI JS, GUNASEKAR P, et al.Levetiracetam associated acute hepatic failure requiring liver transplantation: case report[J]. J Neurol, 2016, 263(4): 814-815. [7] GOHIL JR, AGARWAL TS.Levetiracetam adverse drug reaction: pancytopenia[J]. J Pediatr Neurosci, 2018, 13(1): 116-117. [8] THURMAN DJ, FAUGHT E, HELMERS S, et al.New-onset lesional and nonlesional epilepsy in the US population: Patient characteristics and patterns of antiepileptic drug use[J]. Epilepsy Res, 2019, 157: 106210. [9] China Anti-Epilepsy Association Expert Group. Expert consensus on the application of antiepileptic drugs after craniocerebral surgery (trial implementation)[J]. Chinese Journal of Neurosurgery(中华神经外科杂志), 2012, 27(7): 751-754. [10] SIRSI D, SAFDIEH JE.The safety of levetiracetam[J]. Expert Opin Drug Saf, 2007, 6(3): 241-250. [11] BOU NASIF M, VARADE S, KOUBEISSI MZ.Multifocal myoclonus as a presentation of levetiracetam toxicity[J]. Clin Neurophysiol Pract, 2021, 6: 281-284. [12] KAPOOR P, MCCABE P, KOTHARI MJ.Levetiracetam induced polyneuropathy: a case report[J]. Electromyogr Clin Neurophysiol, 2005, 45(1): 15-17. [13] CHOUINARD MJ, NGUYEN DK, CLÉMENT JF, et al. Catatonia induced by levetiracetam[J]. Epilepsy Behav, 2006, 8(1): 303-307. [14] HWANG ES, SIEMIANOWSKI LA, SEN S, et al.Levetiracetam: an unusual cause of delirium[J]. Am J Ther, 2014, 21(6): e225-e228. [15] EKINCI N, GÜNEŞ S, EKINCI Ö, et al. Levetiracetam-related mania-like symptoms: an adolescent case[J]. Clin Neuropharmacol, 2019, 42(3): 97-98. [16] TURATI M, GLARD Y, AFONSO D, et al.Osteochondral alteration in a child treated with levetiracetam: a rare case of juvenile osteochondritis dissecans of the talar head[J]. J Pediatr Orthop B, 2017, 26(2): 189-192. [17] JADHAV P, KULKARNI T, JADHAV J, et al.Levetiracetam-induced systemic lupus erythematosus[J]. J R Coll Physicians Edinb, 2021, 51(1): 58-60. [18] CHAU K, YONG J, ISMAIL K, et al.Levetiracetam-induced severe acute granulomatous interstitial nephritis[J]. Clin Kidney J, 2012, 5(3): 234-236. [19] KARADAG AS, BILGILI SG, CALKA O, et al.A case of levetiracetam induced bullous pemphigoid[J]. Cutan Ocul Toxicol, 2013, 32(2): 176-178. [20] FUJIKAWA M, KISHIMOTO Y, KAKISAKA Y, et al.Obsessive-compulsive behavior induced by levetiracetam[J]. J Child Neurol, 2015, 30(7): 942-944. [21] XIONG N, HOU L, LU N, et al.Probable levetiracetam-related serum alkaline phosphatase elevation[J]. BMC Neurol, 2012, 12: 97. [22] JU J, ZOU LP, SHI XY, et al.Levetiracetam: probably associated diurnal frequent urination[J]. Am J Ther, 2016, 23(2): e624-e627. [23] FAGAN A, FULD J, SOON E.Levetiracetam-induced eosinophilic pneumonia[J]. BMJ Case Rep. 2017, 2017: bcr2016219121. [24] GUPTA M.Levetiracetam-induced leukocytoclastic vasculitis[J]. Indian J Pharmacol, 2017, 49(1): 124-126. [25] SEREFLICAN B, KARAPINAR T, DUZCU SE, et al.Disseminated eruptive granuloma annulare induced by levetiracetam[J], Cutan Ocul Toxicol, 2017, 36(3): 300-301. [26] MCDONALD D, SULTAN R, VISWANATHAN A, et al.A rare case of levetiracetam and drug-induced idiopathic aseptic meningitis in a pediatric patient[J]. Pharmacotherapy, 2019, 39(1): 109-113. [27] OZDEMIR H, SUMER S, KARABAGLI H, et al.B cell aplasia and hypogammaglobulinemia associated with levetiracetam[J]. Ann Saudi Med, 2018, 38(1): 65-68. [28] LEVY ZD, SLOWEY M, SCHULDER M. Acute generalized exanthematous pustulosis secondary to levetiracetam and valproic acid use[J]. Am J Emerg Med, 2017, 35(7): 1036.e1-1036.e2. [29] NEWSOME SD, XUE LY, JENNINGS T, et al.Levetiracetam-induced diffuse interstitial lung disease[J]. J Child Neurol, 2007, 22(5): 628-630. [30] AKSOY D, CEVIK B, KURT S, et al.Hypokalemia and hypomagnesaemia related to levetiracetam use[J]. J Clin Neurosci, 2014, 21(11): 1989-1990. [31] BORA İ, DEMIR AB, BAŞKAN EB, et al. A case of mycosis fungoides-like lesions developing after levetiracetam therapy[J]. Epilepsy Behav Case Rep, 2014, 2: 192-195. [32] ZHANG JF, PIRYANI R, SWAYAMPAKULA AK, et al.Levetiracetam-induced aggression and acute behavioral changes: a case report and literature review[J]. Clin Case Rep, 2022, 10(3): e05586. [33] DELANTY N, JONES J, TONNER F.Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study[J]. Epilepsia, 2012, 53(1): 111-119. [34] TEINHOFF BJ, STAACK AM.Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience[J]. Ther Adv Neurol Disord, 2019, 12: 1756286419873518. [35] ALTıNÖZ AE, TOSUN AŞ, GÜZEL BB, et al. Levetiracetam induced hypomania: a case report[J]. Ther Adv Drug Saf, 2019, 10: 2042098619876754. [36] STOPPA A, ANMELLA G, DELGADO L, et al.A manic episode with psychotic features associated with levetiracetam: a case report, a proposal of prodromal and discriminative symptoms and a possible pathophysiological mechanism[J]. J Clin Psychopharmacol, 2022, 42(3): 316-317. [37] CHEN B, CHOI H, HIRSCH LJ, et al.Cosmetic side effects of antiepileptic drugs in adults with epilepsy[J]. Epilepsy Behav, 2015, 42: 129-137. [38] ZOU X, HONG Z, ZHOU D.Hair loss with levetiracetam in five patients with epilepsy[J]. Seizure, 2014, 23(2): 158-160. [39] CALABRÒ RS, BRAMANTI P, SPINA E, et al.Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study[J]. Epilepsy Behav, 2013, 29(1): 254-255. [40] DANESE E, MONTAGNANA M, FAVALORO EJ, et al.Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics[J]. Semin Thromb Hemost, 2020, 46(3): 264-274. [41] KIM J, SHIN JW.Levetiracetam-induced thrombocytopenia in a patient with status epilepticus[J]. Epileptic Disord, 2017, 19(1): 104-108. [42] GARCÍA CR, ROMERO BM, OLID-VELILLA M, et al. Pancytopenia associated with levetiracetam in an epileptic woman[J]. BMJ Case Rep, 2016, 7: bcr2016217407. [43] SINGH T, NIAZI M, KARRI K, et al.A rare case of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome with cholecystitis in a patient on levetiracetam[J]. Cureus, 2019, 11(3): e4245. [44] MOINUDDIN IA.Suspected levetiracetam-induced rhabdomyolysis: a case report and literature review[J]. Am J Case Rep, 2020, 21: e926064. |